Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Donanemab was found to slow "clinical decline" by up to 35%, allowing people with the disease to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication.
The health spending watchdog in England is already assessing whether the drug can be used in the NHS.
A new drug has been hailed as a “turning point in the fight against Alzheimer’s” after it was found to slow the progression of the disease.
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.